Related Experiment Video
Updated: Mar 21, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
An overview of antithrombotics in ischemic stroke
Patricia A Schweickert1, John R Gaughen, Elizabeth M Kreitel
1Patricia A. Schweickert is general faculty and an NP at the University of Virginia, Department of Radiology, Interventional Neuroradiology, Charlottesville, Va.; adjunct faculty of nursing at the University of Virginia School of Nursing, Charlottesville, Va; adjunct faculty at Old Dominion University School of Nursing, Norfolk, Va; and contributing faculty of nursing at Walden University School of Nursing, Minneapolis, MN. John R. Gaughen is an interventional neuroradiologist at Sentara Martha Jefferson Hospital, Charlottesville, Va. Elizabeth M. Kreitel is a doctor of pharmacy. Timothy J. Shephard is an administrative coordinator for neuroradiology at the University of Virginia Department of Radiology, Interventional Neuroradiology, Charlottesville, Va. Nina J. Solenski is a stroke neurologist at the University of Virginia, Department of Neurology, Vascular Neurology, Charlottesville, Va. Mary E. Jensen is an interventional neuroradiologist at the University of Virginia, Department of Radiology, Interventional Neuroradiology, Charlottesville, Va.
Antithrombotic medications are crucial for treating and preventing ischemic stroke. This review covers best practices and specific agents for effective stroke management.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Ischemic stroke poses a significant health burden.
- Antithrombotic therapy is a cornerstone of stroke management.
- Evidence-based guidelines are essential for optimal patient outcomes.
Purpose of the Study:
- To review current evidence on antithrombotic medication use in stroke.
- To discuss best practices for treatment and prevention.
- To focus on specific antithrombotic agents employed in stroke care.
Main Methods:
- Comprehensive literature search of antithrombotic therapy in stroke.
- Systematic review of clinical trials and observational studies.
- Analysis of guidelines from major neurological and cardiovascular societies.
Main Results:
- Antithrombotic medications significantly reduce the risk of recurrent ischemic stroke.
- Different agents (e.g., aspirin, clopidogrel, warfarin, DOACs) have specific indications.
- Balancing efficacy and bleeding risk is critical in antithrombotic selection.
Conclusions:
- Optimal antithrombotic selection and duration are key to stroke prevention.
- Adherence to evidence-based guidelines improves patient outcomes.
- Ongoing research is refining antithrombotic strategies for stroke patients.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:28Acute Coronary Syndrome IV: Interprofessional Care